Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Chesler L, Weiss WA.

Semin Cancer Biol. 2011 Oct;21(4):245-55. doi: 10.1016/j.semcancer.2011.09.011. Epub 2011 Sep 21. Review.

PMID:
21958944
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

From fish to FISH: the comparative pathology of neuroblastomas in humans, mice and fish.

Schwab M.

J Cancer Res Clin Oncol. 1999;125(3-4):141-9. Review.

PMID:
10235467
[PubMed - indexed for MEDLINE]
3.

[Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].

Pérel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H.

Arch Pediatr. 2004 Jul;11(7):834-42. Review. French.

PMID:
15234382
[PubMed - indexed for MEDLINE]
4.

Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Huse JT, Holland EC.

Brain Pathol. 2009 Jan;19(1):132-43. doi: 10.1111/j.1750-3639.2008.00234.x. Review.

PMID:
19076778
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Murine models for experimental therapy of pediatric solid tumors with poor prognosis.

Beltinger C, Debatin KM.

Int J Cancer. 2001 May 1;92(3):313-8. Review.

PMID:
11291063
[PubMed - indexed for MEDLINE]
6.

Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Wong PC, Cai H, Borchelt DR, Price DL.

J Mol Neurosci. 2001 Oct;17(2):233-57. Review.

PMID:
11816796
[PubMed - indexed for MEDLINE]
7.

Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.

Owens C, Irwin M.

Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):85-115. doi: 10.3109/10408363.2012.683483. Review.

PMID:
22646747
[PubMed - indexed for MEDLINE]
8.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
[PubMed - indexed for MEDLINE]
9.

Neuroblastoma: management, recurrence, and follow-up.

Lee KL, Ma JF, Shortliffe LD.

Urol Clin North Am. 2003 Nov;30(4):881-90. Review.

PMID:
14680322
[PubMed - indexed for MEDLINE]
10.

Neuroblastoma genetics and phenotype: a tale of heterogeneity.

Speleman F, De Preter K, Vandesompele J.

Semin Cancer Biol. 2011 Oct;21(4):238-44. doi: 10.1016/j.semcancer.2011.07.003. Epub 2011 Aug 4. Review.

PMID:
21839839
[PubMed - indexed for MEDLINE]
11.

Mouse models of childhood cancer of the nervous system.

Dyer MA.

J Clin Pathol. 2004 Jun;57(6):561-76. Review. Erratum in: J Clin Pathol. 2004 Aug;57(8):896.

PMID:
15166259
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The evolution of clinical molecular genetics. Neuroblastoma as a model tumor.

Israel MA.

Am J Pediatr Hematol Oncol. 1986 Summer;8(2):163-72. Review.

PMID:
3526938
[PubMed - indexed for MEDLINE]
13.

Molecularly guided therapy of neuroblastoma: a review of different approaches.

Tonini GP, Pistoia V.

Curr Pharm Des. 2006;12(18):2303-17. Review.

PMID:
16787256
[PubMed - indexed for MEDLINE]
14.

Spontaneous and engineered mutant mice as models for experimental and comparative pathology: history, comparison, and developmental technology.

Roths JB, Foxworth WB, McArthur MJ, Montgomery CA, Kier AB.

Lab Anim Sci. 1999 Feb;49(1):12-34. Review.

PMID:
10090091
[PubMed - indexed for MEDLINE]
15.

Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes.

Singh M, Murriel CL, Johnson L.

Cancer Res. 2012 Jun 1;72(11):2695-700. doi: 10.1158/0008-5472.CAN-11-2786. Epub 2012 May 16. Review.

PMID:
22593194
[PubMed - indexed for MEDLINE]
Free Article
16.

Neuroblastoma--clinical applications of molecular parameters.

Brodeur GM.

Brain Pathol. 1990 Sep;1(1):47-54. Review.

PMID:
1669693
[PubMed - indexed for MEDLINE]
17.

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Hogarty MD.

Cancer Lett. 2003 Jul 18;197(1-2):173-9. Review.

PMID:
12880978
[PubMed - indexed for MEDLINE]
18.

Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.

Øra I, Eggert A.

Semin Cancer Biol. 2011 Oct;21(4):217-28. doi: 10.1016/j.semcancer.2011.07.002. Epub 2011 Jul 20. Review.

PMID:
21798350
[PubMed - indexed for MEDLINE]
19.

Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies.

Coco S, Tonini GP, Stigliani S, Scaruffi P.

Curr Pharm Des. 2009;15(4):448-55. Review.

PMID:
19199972
[PubMed - indexed for MEDLINE]
20.

Genetically engineered mouse models in cancer research.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.

Adv Cancer Res. 2010;106:113-64. doi: 10.1016/S0065-230X(10)06004-5. Review.

PMID:
20399958
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk